Current Report Filing (8-k)
August 19 2016 - 5:08PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
August 17, 2016
AKERS
BIOSCIENCES, INC.
(Exact
name of registrant as specified in its charter)
New
Jersey
|
|
333-190456
|
|
22-2983783
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification
No.)
|
201
Grove Road
Thorofare,
NJ 080086
(Address
of Principal Executive Offices)
(856)
848-2116
Registrant’s
telephone number, including area code
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
1.01 Entry into a Material Definitive Agreement.
On
August 17, 2016, Akers Biosciences, Inc. (the “Company”) entered into a Settlement Deed (the “Settlement Agreement”)
by and among the Company, Chuberworkx Guernsey Limited (“Chube”), Thirty Six Strategies, LLC (“36S”),
Gavin Moran (“Mr. Moran”) and Frank Runge (“Mr. Runge”) (each, a “Party” and, collectively,
the “Parties”) to resolve disputes related to (i) the Company’s claims brought against Chube in United States
District Court, District of New Jersey for outstanding amounts due to the Company pursuant to that certain promissory note (the
“Note”) issued in favor of Chube on December 31, 2014 (“Dispute 1”); (ii) various claims brought by Chube
against the Company brought in The High Court of Justice, Queen’s Bench Division Commercial Court, Royal Courts of Justice,
United Kingdom arising out that certain Licensing and Supply agreement, as amended (the “License Agreement”), pursuant
to which Chube was granted a worldwide, exclusive license to import, offer for sale, sell, distribute, use, promote or label certain
products using the Company’s intellectual property in a suit brought in The High Court of Justice, Queen’s Bench Division
Commercial Court, Royal Courts of Justice, United Kingdom (“Dispute 2”) and (iii) various claims brought by the Company
against 36S, Mr. Moran and Mr. Runge in the United States District Court, District of New Jersey, related to that certain Distribution
Agreement entered into by and between the Company and 36S on October 5, 2015 (“Dispute 3” and, together with Dispute
1 and Dispute 2, the “Disputes”).
Pursuant
to the Settlement Agreement, all of the Disputes have been settled and all of the proceedings related to such have been dismissed.
Under the terms of the Settlement Agreement, the Company will recover the full outstanding principal amount of the Note during
the 2016 fiscal year in the form of $750,000 worth of BreathScan® Alcohol Detector stock to inventory (which the Company intends
to subsequently sell) and $500,000 in cash (the “Cash Payment”). In addition, the Settlement Agreement also allows
the Company to market and sell all of the Company’s breath technology tests worldwide, unencumbered by any past and/or future
claims by Chube under the Licensing Agreement. Pursuant to the Settlement Agreement, Chube no longer holds any rights pertaining
to the Company’s BreathScan® technology.
In
return for the Company regaining the full rights to sell its breath technology products, among other things, Chube will receive
a royalty of 5% of the Company’s gross revenues (the “Chube Royalty”) totaling $5,000,000, after which Chube
will no longer be entitled to receive any royalties and the Company shall have no further obligations to Chube. The Settlement
Agreement further allows the Company to retain 50% of the Chube Royalty until the Cash Payment has been made.
In connection with the Settlement Agreement,
on August 17, 2016, the Company and Chube entered into a Security Agreement pledging all of the Company’s assets including
all inventory and receivables (but excluding the specific assets referred to in the Settlement Agreement) in order to secure the
Chube Royalty. Upon payment of the Chube Royalty to Chube the Security Agreement is terminated and the Company’s assets become
unencumbered.
Item
2.03.
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
Item
1.01 is hereby incorporated by reference.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
AKERS BIOSCIENCES, INC.
|
|
|
|
Date:
August 19, 2016
|
By:
|
/s/
John Gormally
|
|
|
John
Gormally
|
|
|
Chief
Executive Officer
|
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Jun 2024 to Jul 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Jul 2023 to Jul 2024